Academic History
Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, is a Professor of Biological Cancer Therapies at The Institute of Cancer Research (ICR), London, UK. He studied medicine at St Bartholomew’s Hospital, London, UK, and specialized in head and neck cancer as a PhD student at Hammersmith Hospital, London, UK. He then went on to complete post-doctorate research in molecular medicine at the Mayo Clinic, Rochester, MN.
His current roles include Joint Head of the Division of Radiotherapy and Imaging at The Royal Marsden NHS Foundation Trust and consultant at The Royal Marsden NHS Foundation Trust, London, UK. Within the ICR, he leads the Targeted Therapy Team Leader in the Division of Cancer Biology. Much of his laboratory work focusing on head and neck cancers and melanoma is quickly translated into clinical trials, with 400 articles published with his name.
Speaking on novel targeted radio- and immunotherapies in solid tumors
Prof. Harrington specializes in developing new targeted treatments, his research group focusing on the interface between biologically targeted agents and standard-of-care therapies such as radiotherapy and chemotherapy. He has been a part of multiple clinical trials for solid tumors such as the INTERLINK-1 study which investigated a novel combination treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma. He is also spearheading the VERSATILLE-003 trial, which is investigating HPV16-targeted immunotherapies for human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC).
